Should we screen for prostate cancer?: Men over 50 have a right to decide for themselves

BMJ

Volumn 314, Issue 7086, 1997, Pages 989-

  Woolf, Steven H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; EDITORIAL; HEALTH CARE POLICY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SCREENING;

ALTERNATIVES; AUTONOMY; CANCER; CLINICAL APPROACH/SOURCE; COSTS AND BENEFITS; GREAT BRITAIN; HEALTH CARE AND PUBLIC HEALTH; MALES; NATIONAL HEALTH SERVICE; RESOURCE ALLOCATION; RISKS AND BENEFITS; TECHNOLOGY ASSESSMENT; UNCERTAINTY; VALUES;

AGED; CHOICE BEHAVIOR; DISCLOSURE; GREAT BRITAIN; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PERSONAL AUTONOMY; PROSTATIC NEOPLASMS; RESOURCE ALLOCATION; RISK ASSESSMENT; SOCIAL VALUES; STATE MEDICINE; UNCERTAINTY;

EID: 85008309064     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.314.7086.989     Document Type: Editorial

References (14)

1. Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med 1995, 333: 1401–1405.
2. Chamberlain J, Melia J, Moss S, Brown J. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1997; 1(3).
3. Selley S, Donovan J, Faulkner A, Coast J, Gillat D. Diagnosis, management and screening of early localised prostate cancer: a systematic review. Health Technol Assess 1997; 1(2).
4. NHS Centre for Reviews and Dissemination. Screening for prostate cancer. Effectiveness Matters 1997; 2(2).
5. SBU. Mass screening for prostate cancer. Int J Cancer 1996; 9(suppl):1–72.
6. US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams and Wilkins, 1996: 119–34.
7. Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa: Canada Communication Group, 1994: 812–23.
8. Australian Health Technology Advisory Committee. Prostate cancer screening. Canberra: Australian Health Technology Advisory Committee, 1996.
9. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA 1994; 272: 773–80.
10. Flood AB, Wennberg JE, Nease RF Jr, Fowler FJ, Ding J, Hynes LM. The importance of patient preference in the decision to screen for prostate cancer. J Gen Intern Med 1996; 11: 2342–2349.
11. Wolf AMD, Nasser JF, Wolf AM, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med 1996; 156: 1333–1336.
12. Lidz CW, Meisel A, Osterweis M, et al. Barriers to informed consent. Ann Intern Med 1983; 99: 539–43.
13. NHS Centre for Reviews and Dissemination. Screening for prostate cancer: the evidence. Information for men considering or asking for PSA tests. York: University of York, NHS Centre for Reviews and Dissemination, 1997. (Available from National Health Information Service, freephone 0800 66 55 44).
14. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343: 251–254.